Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein
Name
Rodriguez-Martinez-2015-Antibody Derived Pep.pdf
Size
5.44 MB
Format
Adobe PDF
Checksum (MD5)
163804e0877e99b2cb476891f75fd1d2
Author(s)
Rodriguez-Martinez, Luis Mario
Marquez-Ipina, Alan Roberto
Lopez-Pacheco, Felipe
Perez-Chavarria, Roberto
Gonzalez-Vazquez, Juan Carlos
Gonzalez-Gonzalez, Everardo
Trujillo-de Santiago, Grissel
Ponce-Ponce de Leon, Cesar Alejandro
Zhang, Yu Shrike
Dokmeci, Mehmet Remzi
Date Issued
October 2015
Journal
PLOS ONE
Publisher
Public Library of Science
Citation
Rodriguez-Martinez, Luis Mario, Alan Roberto Marquez-Ipina, Felipe Lopez-Pacheco, Roberto Perez-Chavarria, Juan Carlos Gonzalez-Vazquez, Everardo Gonzalez-Gonzalez, Grissel Trujillo-de Santiago, et al. “Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein.” Edited by Gourapura J Renukaradhya. PLoS ONE 10, no. 10 (October 21, 2015): e0135859.
Version
Final published version
Abstract
Background
Current Ebola virus (EBOV) detection methods are costly and impractical for epidemic scenarios. Different immune-based assays have been reported for the detection and quantification of Ebola virus (EBOV) proteins. In particular, several monoclonal antibodies (mAbs) have been described that bind the capsid glycoprotein (GP) of EBOV GP. However, the currently available platforms for the design and production of full-length mAbs are cumbersome and costly. The use of antibody fragments, rather than full-length antibodies, might represent a cost-effective alternative for the development of diagnostic and possibly even therapeutic alternatives for EBOV.
Methods/Principal Findings
We report the design and expression of three recombinant anti-GP mAb fragments in Escherichia coli cultures. These fragments contained the heavy and light variable portions of the three well-studied anti-GP full-length mAbs 13C6, 13F6, and KZ52, and are consequently named scFv-13C6, scFv-13F6, and Fab-KZ52, respectively. All three fragments exhibited specific anti-GP binding activity in ELISA experiments comparable to that of full-length anti-GP antibodies (i.e., the same order of magnitude) and they are easily and economically produced in bacterial cultures.
Conclusion/Significance
Antibody fragments might represent a useful, effective, and low cost alternative to full-length antibodies in Ebola related capture and diagnostics applications.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1371/journal.pone.0135859
